EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer

Francesca Jackson-Spence iD, James Larkin iD, Poulam Patel iD, Begoña P Valderrama, Alejo Rodriguez-Vida, Hilary Glen iD, Fiona C Thistlethwaite iD, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Merrida Childress iD, Wenshu Li und 10 weitere

Journal of Clinical Oncology · 20.04.2026 · 44 (12) · 1076-1082

DOI: 10.1200/jco-25-01840 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2026. Verfasst von Francesca Jackson-Spence und 21 weiteren Autor:innen. Beteiligte Einrichtung: Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The CALYPSO study demonstrated activity of savolitinib and durvalumab in MET -driven papillary renal cancer (PRC). We report final efficacy outcomes and exploratory circulating tumor DNA (ctDNA) biomarker analysis. METHODS This single-arm phase II study evaluated savolitinib and durvalumab in treatment-naïve or pretreated PRC. End points included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). FoundationOne CDx assessed DNA alterations and MET /PD-L1 or MET /tumor mutational burden (TMB) copositivity. ctDNA collected at baseline and on treatment was correlated with outcomes. RESULTS At 41-months median follow-up, ORR was 34% (95% CI, 20.0 to 51.0) in the intention-to-treat (ITT) population (N = 41) and 53% (95% CI, 28.0 to 77.0) in MET -driven patients (n = 17). Median PFS was 6.5 (95% CI, 2.7 to 12.0) versus 13.9 months (95% CI, 2.9 to 23.8), and OS was 18.3 (95% CI, 7.3 to 30.7) versus 27.4 months (95% CI, 9.3 to 37.4), in the ITT population and the MET -driven population, respectively. PD-L1 (66% positive) and TMB (median 2.5 mut/Mb) status did not correlate with response. Baseline ctDNA positivity (10/21) correlated with shorter OS (median 7.3 v 33.3 months), while ctDNA clearance and mean variant allele frequency reduction correlated with improved OS (median 31.3 v 7.2 and 31.3 v 15.5 months, respectively). CONCLUSION Savolitinib plus durvalumab shows OS in MET -driven PRC, supporting the ongoing SAMETA RIII trial (ClinicalTrials.gov identifier: NCT05043090 ). ctDNA may be a useful predictive biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellHumansCirculating Tumor DNAFemaleMaleMiddle AgedAgedBiomarkers, TumorProgression-Free SurvivalProto-Oncogene Proteins c-metAdultTriazinesMutation

Substanzen

Antibodies, MonoclonaldurvalumabCirculating Tumor DNABiomarkers, TumorProto-Oncogene Proteins c-metTriazines

Autor:innen und Institutionen

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • The Royal Marsden Hospital, London, United Kingdom.
  • Nottingham University Hospital NHS Trust, Nottingham, United Kingdom.
  • Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Hospital del Mar-CIBERONC, Hospital del Mar Research Institute, Barcelona, Spain.
  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.

ORCID-Profile: Francesca Jackson-Spence, James Larkin, Poulam Patel, Hilary Glen, Fiona C Thistlethwaite, Merrida Childress, Amaya Gascó, Aleksandra Markovets, Charlotte Ackerman, Bernadett E Szabados, Thomas Powles, Cristina Suárez

Zitieren

APA

Jackson-Spence, F., Larkin, J., Patel, P., Valderrama, B. P., Rodriguez-Vida, A., Glen, H., Thistlethwaite, F. C., Ralph, C., Srinivasan, G., Mendez-Vidal, M. J., Childress, M., Li, W., Boyle, P., Gascó, A., Markovets, A., Hartmaier, R., Ackerman, C., Szabados, B. E., Priyadarshini, G., …, & Suárez, C. (2026). CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. Journal of Clinical Oncology, 44(12), 1076-1082. https://doi.org/10.1200/jco-25-01840

Vancouver

Jackson-Spence F, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, et al. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. Journal of Clinical Oncology. 2026;44(12):1076-1082. doi:10.1200/jco-25-01840

BibTeX
@article{JacksonSpence2026,
  author = {Jackson-Spence, Francesca and Larkin, James and Patel, Poulam and Valderrama, Begoña P and Rodriguez-Vida, Alejo and Glen, Hilary and Thistlethwaite, Fiona C and Ralph, Christy and Srinivasan, Gopalakrishnan and Mendez-Vidal, Maria Jose and Childress, Merrida and Li, Wenshu and Boyle, Patrick and Gascó, Amaya and Markovets, Aleksandra and Hartmaier, Ryan and Ackerman, Charlotte and Szabados, Bernadett E and Priyadarshini, Garima and Jamal, Fahmida and Powles, Thomas and Suárez, Cristina},
  title = {CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {12},
  pages = {1076--1082},
  doi = {10.1200/jco-25-01840}
}
Kostenlos starten →